Company: BIVIW
Filing Date: 2025-10-06
Form Type: POS AM
Source: 0001520138-25-000294
Chunk: 21

Company: BIOVIE INC.
Filing Date: 2025-10-06
Form: POS AM
Chunk 21
---
 These statements relate to analyses and other information that are based on forecasts of future results,
estimates of amounts not yet determinable and assumptions of management. All statements contained herein that are not clearly historical
in nature are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,”
“may,” “will,” “could,” “leading,” “intend,” “contemplate,” “shall”
and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are subject to a variety
of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed
or implied by the forward-looking statements. The section in this prospectus entitled “Risk Factors” and the sections in our
Annual Report on Form 10-K for the fiscal year ended June 30, 2025 entitled “Business,” “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” as well as other sections in this prospectus and the
documents or reports incorporated by reference into this prospectus, discuss some of the factors that could contribute to these differences.
Forward-looking statements in this prospectus and the documents incorporated by reference herein include, but are not limited to, statements
with respect to:

| - | our limited operating history and experience in developing and manufacturing 
 drugs;                                                                       |

| - | none of our products are approved for commercial sale; |

| - | our substantial capital needs; |

| - | product development risks; |

| - | our lack of sales and marketing personnel; |

| - | regulatory, competitive and contractual risks; |

| - | no assurance that our product candidates will obtain regulatory     
 approval or that the results of clinical studies will be favorable; |

| - | risks related to our intellectual property rights; |

| - | the volatility of the market price and trading volume in our Common 
 Stock;                                                              |

| - | the risk that our Common Stock will be delisted from Nasdaq; |

| - | the absence of liquidity in our Common Stock; |

| - | the risk of substantial dilution from future issuances of our equity 
 securities; and                                                      |

| - | the other risks set forth herein and in the documents incorporated 
 by reference herein under the caption “Risk Factors.”              |

The foregoing does not represent an exhaustive list
of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with. The factors
set forth above under “